Trastuzumab has been used to manage both early and metastatic HER2-postive breast cancer and has significantly improved the survival of these patients and become the standard of care, according to Arlene Chan, MB BS, FRACP, MMed, writing in Chinese Clinical Oncology.
Trastuzumab has been used to manage both early and metastatic HER2-postive breast cancer with encouraging results. It has significantly improved the survival of these patients and become the standard of care, according to an editorial by Arlene Chan, MBBS, FRACP, MMed, writing in Chinese Clinical Oncology. However, the cost of 12 months of adjuvant trastuzumab therapy, the standard duration of treatment, as well as the cost associated with indefinite use in a metastatic setting, limits patient access to this life-saving drug.
According to Chan, a study published in the Lancet Oncology that evaluated trastuzumab’s limited availability in China, India, and Russia (which make up 40% of the world’s population) showed that only one-third of HER2-positive breast cancer patients in China had access to trastuzumab. The study also demonstrated equivalence of the biosimilar, CT-P6, with reference trastuzumab in the primary outcome measure of pathological complete response (pCR). In line with the FDA’s guidance on using pCR as an endpoint in high-risk early-stage breast cancer following neoadjuvant therapy to support accelerated drug approval, the use of pCR is an appropriate clinical endpoint to demonstrate equivalence of the 2 molecules, said Chan.
With respect to safety, incidence of treatment emergent adverse events appeared to be balanced between the 2 agents. The administration of concurrent anti-HER2 agent with the anthracycline component of neoadjuvant treatment did not show differences in rates of symptomatic cardiac dysfunction, though cardiac function follow-up was only reported until the end of the neoadjuvant phase of treatment. Investigators will also perform a follow-up for disease events for a minimum of 3 years from the enrollment of the last patient to ensure that the equivalent efficacy is maintained.
According to Chan, the real benefit of the study will be determining whether the presumed lower drug costs of the biosimilar translate into greater utilization of this targeted therapy, especially for those who do not currently receive this treatment. The healthcare community is waiting to see whether increasing availability of trastuzumab biosimilar agents will change clinical practice as the financial barriers are lowered.
It will also be important, says Chan, to measure certain outcomes as more biosimilars enter the clinical setting for breast cancer and HER2-positive solid tumors. These outcomes will include institutional and national data collection to show that more patients are receiving this therapy, as well as cost savings that are presumed for health care providers.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
February 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
A Banner Year for Biosimilars: The 19 FDA Approvals From 2024
January 21st 2025In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options and market competition.
Biosimilars Drive Cost Savings and Achieve 53% Market Share Across Treatment Areas
January 16th 2025Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar competition, according to Samsung Bioepis’ most recent market report, showcasing notable pricing trends and market share disparities across therapeutic areas.